OREANDA-NEWS. Protek Group (PRTK:RTS, MICEX), one of the major pharmaceutical companies in Russia operating in all segments of the pharmaceutical market (production, distribution, and retail sales), announces its unaudited financial results for Q1-2013.

In Q1-2013, the Group’s consolidated revenue increased by 21.5% y-o-y to RUB 34,689 mln.

Protek Group’s EBITDA was up 15.6% y-o-y to RUB 1,184 mln.

In Q1-2013, the Group's net income increased by 17.7% to RUB 847 mln.

Financial Highlights

Revenue, RUB mln.

EBITDA, RUB mln.

Net income

Q1-2013

34,689

1,184

847

Q1-2012

28,539

1,024

719

Change, 2013/2012, %

21.5%

15.6%

17.7%

Mr. Vadim Muzyayev, President of Protek Group, has commented on the Q1-2013 financial results: "Over the reporting period, the Protek Group has shown strong financial performance as a result of effective strategies implemented across our business segments. In Distribution, we kept on strengthening CV Protek's position in the commercial market to expand our customer base. In Q1-2013, CV Protek boosted its product range and sales (by volume), along with driving the average package price up through robust product range performance. From early in the year, the Retail Sales Segment (Rigla pharmacy chain) was boosting organic growth rates to reach a historical high of 44 pharmacies opened in Q1-2013. Our Production Segment, along with reducing licensed generics output, was active in expanding its own brand share to drive it up by 18%."